Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 OLP4 vaccine + poly-ICLC + montanide
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
NY-ESO-1 OLP4 vaccine + poly-ICLC + montanide is a therapeutic cancer vaccine combination designed to induce immune responses against tumors expressing the cancer-testis antigen NY‑ESO‑1. The formulation consists of four overlapping long peptides (OLP4) derived from the immunogenic region of the NY‑ESO‑1 protein, combined with two adjuvants: Montanide ISA 51 VG (a water-in-oil emulsion that enhances antigen presentation) and polyinosinic-polycytidylic acid stabilized with poly-L‑lysine and carboxymethylcellulose (poly‑ICLC), a synthetic double-stranded RNA that acts as a toll-like receptor 3 agonist to further stimulate innate immunity. This combination aims to activate both CD8+ and CD4+ T cell responses against tumor cells expressing NY‑ESO‑1, particularly in patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in remission after standard therapy[5][6]. The approach is intended to overcome HLA restriction by covering most immunogenic epitopes within residues 79–173 of the protein[6].
- Other names
- NY-ESO-1 overlapping long peptides + Montanide ISA-51 + Poly-ICLCNY-ESO-1 OLP4 vaccineNY-ESO1 OLP4 vaccineNY-ESO 1 OLP4 vaccine
02
Targets
MHC II (Major histocompatibility complex class II receptor)NY-ESO-1 TCR (NY-ESO-1-specific T-cell receptor)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on NY-ESO-1 OLP4 vaccine + poly-ICLC + montanide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 OLP4 vaccine + poly-ICLC + montanide.